Inhibition of matrix metalloproteinase-9 activity by trandolapril after middle cerebral artery occlusion in rats

Hypertension Research

Volumn 30, Issue 5, 2007, Pages 469-475

  Tanaka, Hidekazu ^a   Takai, Shinji ^a   Jin, Denan ^a   Furubayashi, Keiichi ^a   Inoue, Nao ^a   Kajimoto, Yoshinaga ^a   Miyatake, Shin Ichi ^a   Kuroiwa, Toshihiko ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotenain converting enzyme; Cerebral infarction; Inhibitor; Macrophage

Indexed keywords

GELATINASE A; GELATINASE B; PLACEBO; TRANDOLAPRIL;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ARTERY; BRAIN DAMAGE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; POST HOC ANALYSIS; RAT; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; INDOLES; INFARCTION, MIDDLE CEREBRAL ARTERY; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED WKY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 34250693189     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.469     Document Type: Article

References (31)

1. Fukuhara M, Geary RL, Diz DI, et al: Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000; 35: 353-359.
2. Sadoshima J: Cytokine actions of angiotensin II. Circ Res 2000; 86: 1187-1189.
3. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
4. Mabuchi T, Kitagawa K, Ohtsuki T, et al: Contribution of microglia/macrophages to expansion of infarction and response of oligodendrocytes after focal cerebral ischemia in rats. Stroke 2000; 31: 1735-1743.
5. Ganten D, LanO RE, Lehmann E, Unger T: Brain angiotensin: on the way to becoming a well-studied neuropeptide system. Biochem Pharmacol 1984; 33: 3523-3528.
6. Okamoto K, Takai S, Sasaki S, Miyazaki M: Trandolapril reduces infarction area after middle cerebral artery occlusion in rats. Hypertens Res 2002; 25: 583-588.
7. Yurchenco PD, Schittny JC: Molecular architecture of basement membranes. FASEB J 1990; 4: 1577-1590.
8. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases, and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
9. Goetzl EJ, Banda MJ, Leppert D: Matrix metalloproteinases in immunity. J Immunol 1996; 156: 1-4.
10. Risau W, Wolburg H: Development of the blood-brain barrier. Trends Neurosci 1990; 13: 174-178.
11. Rosenberg GA: Matrix metalloproteinases in brain injury. J Neurotrauma 1995; 12: 833-842.
12. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC: Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998; 29: 1020-1030.
13. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ: Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 1995; 26: 2120-2126.
14. Sorbi D, Fadly M, Hicks R, Alexander S, Arbeit L: Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int 1993; 44: 1266-1272.
15. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR: Cardiac remodelling in end stage heart failure: Upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 2002; 88: 525-530.
16. Ikeda N, Nonoguchi N, Zhao MZ, et al: Bone marrow stromal cells that enhanced fibroblast growth factor-2 secretion by herpes simplex virus vector improve neurological outcome after transient focal cerebral ischemia in rats. Stroke 2005; 36: 2725-2730.
17. Takai S, Jin D, Sakaguchi M, Miyazaki M: Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors. Hypertens Res 2004; 27: 213-219.
18. Kishi K, Muramatsu M, Jin D, et al: The effects of chymase on the matrix metalloproteainase-2 activation of neointimal hyperplasia after balloon injury in dogs. Hypertens Res 2007; 30:77-83.
19. Arenas IA, Xu Y, Lopez-Jaramillo P, Davidge ST: Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-α. Am J Physiol Cell Physiol 2004; 286: C779-C784.
20. Rouet-Benzineb P, Gontero B, Dreyfus P, Lafuma C: Angiotensin II induces nuclear factor-κB activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol 2000; 32: 1767-1778.
21. Miyazaki M, Kawamoto T, Okunishi H: Vascular affinity of trandolapril. Am J Hypertens 1995; 8: 63S-67S.
22. Gohlke P, Urbach H, Scholkens B, Unger T: Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors. J Pharmacol Exp Ther 1989; 249 609-616.
23. Moursi MG, Ganten D, Lang RE, Unger T: Antihypertensive action and inhibition of tissue converting enzyme (CE) by three prodrug CE inhibitors, enalapril, ramipril and perindopril in stroke-prone spontaneously hypertensive rats. J Hypertens 1986; 4 (Suppl 3): S495-S498.
24. Takai S, Song K, Tanaka T, Okunishi H, Miyazaki M: Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Life Sci 1996; 59: PL331-PL336.
25. Hamai M, Iwai M, Ide A, et al: Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress. Neuropharmacology 2006; 51: 822-828.
26. Lou M, Blume A, Zhao Y, et al: Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J Cereb Blood Flow Metab 2004; 24: 536-547.
27. Lu Q, Zhu YZ, Wong PT: Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport 2005; 16: 1963-1967.
28. Kagiyama T, Kagiyama S, Phillips MI: Expression of angiotensin type 1 and 2 receptors in brain after transient middle cerebral artery occlusion in rats. Regul Pept 2003; 110: 241-247.
29. Iwai M, Liu HW, Chen R, et al: Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110: 843-848.
30. Copin JC, Goodyear MC, Gidday JM, et al: Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice. Eur J Neurosci 2005; 22: 1597-1608.
31. Koistinaho M, Malm TM, Kettunen MI, et al: Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-eficient mice. J Cereb Blood Flow Metab 2005; 25: 460-467.